• Je něco špatně v tomto záznamu ?

Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain inter-individual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia

P. Pokorná, D. Michaličková, S. Völler, K. Hronová, D. Tibboel, O. Slanař, EH. Krekels

. 2022 ; 74 (2) : 107-115. [pub] 20201027

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019024

BACKGROUND: The current study uses a population modeling approach to evaluate and quantify the impact of severity of asphyxia and hypoxic-ischemic encephalopathy (HIE) on the pharmacokinetics of phenobarbital in asphyxiated newborns treated with therapeutic hypothermia. METHODS: Included newborns received phenobarbital (the TOBY trial protocol). 120 plasma samples were available from 50 newborns, median (IQR) weight 3.3 (2.8-3.5) kg and gestational age 39 (39-40) weeks. NONMEM® version 7.2 was used for the data analysis. Age, body weight, sex, concomitant medications, kidney and liver function markers, as well as severity parameters of asphyxia and HIE were tested as potential covariates of pharmacokinetics of phenobarbital. Severe asphyxia was defined as pH of arterial umbilical cord blood ≤7.1 and Apgar 5 ≤5, and severe HIE was defined as time to normalization of amplitude-integrated electroencephalography (aEEG) >24 h. RESULTS: Weight was found to be the only statistically significant covariate for the volume of distribution. At weight of 1 kg volume of distribution was 0.91 L and for every additional kg it increased in 0.91 L. Clearance was 0.00563 L/h. No covariates were statistically significant for the clearance of phenobarbital. CONCLUSIONS: Phenobarbital dose adjustments are not indicated in the studied population, irrespective of the severity of asphyxia or HIE.

000      
00000naa a2200000 a 4500
001      
bmc22019024
003      
CZ-PrNML
005      
20220804135257.0
007      
ta
008      
220720s2022 it f 000 0|eng||
009      
AR
024    7_
$a 10.23736/S2724-5276.20.05740-0 $2 doi
035    __
$a (PubMed)33107271
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Pokorná, Pavla $u Department of Pediatrics and Inherited Metabolic Disorders, General University Hospital $u st Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, General University Hospital $u st Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain inter-individual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia / $c P. Pokorná, D. Michaličková, S. Völler, K. Hronová, D. Tibboel, O. Slanař, EH. Krekels
520    9_
$a BACKGROUND: The current study uses a population modeling approach to evaluate and quantify the impact of severity of asphyxia and hypoxic-ischemic encephalopathy (HIE) on the pharmacokinetics of phenobarbital in asphyxiated newborns treated with therapeutic hypothermia. METHODS: Included newborns received phenobarbital (the TOBY trial protocol). 120 plasma samples were available from 50 newborns, median (IQR) weight 3.3 (2.8-3.5) kg and gestational age 39 (39-40) weeks. NONMEM® version 7.2 was used for the data analysis. Age, body weight, sex, concomitant medications, kidney and liver function markers, as well as severity parameters of asphyxia and HIE were tested as potential covariates of pharmacokinetics of phenobarbital. Severe asphyxia was defined as pH of arterial umbilical cord blood ≤7.1 and Apgar 5 ≤5, and severe HIE was defined as time to normalization of amplitude-integrated electroencephalography (aEEG) >24 h. RESULTS: Weight was found to be the only statistically significant covariate for the volume of distribution. At weight of 1 kg volume of distribution was 0.91 L and for every additional kg it increased in 0.91 L. Clearance was 0.00563 L/h. No covariates were statistically significant for the clearance of phenobarbital. CONCLUSIONS: Phenobarbital dose adjustments are not indicated in the studied population, irrespective of the severity of asphyxia or HIE.
650    _2
$a dospělí $7 D000328
650    _2
$a asfyxie $x komplikace $x farmakoterapie $7 D001237
650    12
$a asfyxie novorozenců $x komplikace $x farmakoterapie $7 D001238
650    _2
$a lidé $7 D006801
650    12
$a terapeutická hypotermie $x metody $7 D007036
650    12
$a mozková hypoxie a ischemie $x terapie $7 D020925
650    _2
$a novorozenec $7 D007231
650    _2
$a fenobarbital $x farmakokinetika $x terapeutické užití $7 D010634
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michaličková, Danica $u st Faculty of Medicine, Charles University, Prague, Czech Republic - marrtta@gmail.com
700    1_
$a Völler, Swantje $u st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hronová, Karolina $u st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Tibboel, Dick $u Department of Pediatrics and Inherited Metabolic Disorders, General University Hospital $u Institute of Pharmacology, General University Hospital
700    1_
$a Slanař, Ondřej $u st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Krekels, Elke H $u st Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00209466 $t Minerva pediatrics $x 2724-5780 $g Roč. 74, č. 2 (2022), s. 107-115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33107271 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135250 $b ABA008
999    __
$a ok $b bmc $g 1822573 $s 1170267
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 74 $c 2 $d 107-115 $e 20201027 $i 2724-5780 $m Minerva pediatrics $n Minerva Pediatr (Torino) $x MED00209466
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace